Oxford Immunotec Global PLC (NASDAQ:OXFD) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $11.96 and last traded at $14.06, with a volume of 322000 shares. The stock had previously closed at $14.46.

Several brokerages recently issued reports on OXFD. Piper Jaffray Companies cut their target price on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 31st. BTIG Research set a $21.00 target price on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Monday, December 18th. Robert W. Baird restated a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. BidaskClub upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Finally, ValuEngine downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $19.75.

The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30. The firm has a market cap of $292.21, a price-to-earnings ratio of -5.55 and a beta of -0.09.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now owns 17,778 shares in the company, valued at $237,336.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 8.11% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its holdings in Oxford Immunotec Global by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after buying an additional 1,500 shares during the last quarter. Voya Investment Management LLC raised its holdings in Oxford Immunotec Global by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after buying an additional 1,845 shares during the last quarter. Rhumbline Advisers raised its holdings in Oxford Immunotec Global by 9.1% during the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after buying an additional 2,053 shares during the last quarter. Vanguard Group Inc. raised its holdings in Oxford Immunotec Global by 5.4% during the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock worth $1,161,000 after buying an additional 3,507 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its holdings in Oxford Immunotec Global by 6.8% during the second quarter. TIAA CREF Investment Management LLC now owns 76,094 shares of the company’s stock worth $1,280,000 after buying an additional 4,840 shares during the last quarter. Hedge funds and other institutional investors own 89.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global (OXFD) Hits New 52-Week Low at $11.96” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/oxford-immunotec-global-oxfd-hits-new-52-week-low-at-11-96/1800877.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.